ARCT news

Arcturus confirms receipt of FDA clearance for its LEAP mRNA platform technology. This regulatory milestone underpins the development of its COVID-19 vaccine candidate, LURV126. Industry observers view this clearance as a vote of confidence in the platform's safety and scalability.

Arcturus Therapeutics entered a strategic collaboration with Thermo Fisher Scientific to manufacture its cystic fibrosis candidate ARCT-032. This partnership accelerates development and secures late-stage manufacturing rights for the partner.

Arcutis Biotherapeutics amended its director compensation program, increasing board retainers to $50,000 annually and initial equity awards to $350,000. The changes affect compensation structure for non-employee directors and committee service.